{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:59:00Z","timestamp":1747184340737,"version":"3.40.5"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec><jats:title>Hintergrund<\/jats:title><jats:p>Prim\u00e4r kutane Lymphome (PCL) unterscheiden sich oft stark im klinischen Verhalten und in der Prognose von systemischen Lymphomen des gleichen histopathologischen Typs. Ziel der Studie war es, die Verteilung der PCL\u2010Subtypen, die Zeitspanne von der Krankheitsmanifestation bis zur Diagnosestellung, den Stellenwert diagnostischer Verfahren, das Auftreten von Zweittumoren und die verschiedenen Behandlungsmodalit\u00e4ten im Rahmen des Krankheitsverlaufs zu untersuchen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patienten und Methodik<\/jats:title><jats:p>Retrospektive Analyse von 152 Patienten mit PCL, die von 2010\u20132012 an der Universit\u00e4ts\u2010Hautklinik T\u00fcbingen behandelt wurden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ergebnisse<\/jats:title><jats:p>105 Patienten mit prim\u00e4r kutanem T\u2010Zell\u2010Lymphom (CTCL) (69,1\u00a0%) und 47 Patienten mit prim\u00e4r kutanem B\u2010Zell\u2010Lymphom (CBCL) (30,9\u00a0%) wurden eingeschlossen. Die Zeitspanne von der Krankheitsmanifestation bis zur Diagnose betrug durchschnittlich vier Jahre. Mycosis fungoides (MF) (47,4\u00a0%) wurde am h\u00e4ufigsten diagnostiziert. Die First\u2010Line\u2010Therapien umfassten hier entweder eine alleinige Phototherapie (PUVA, n\u00a0=\u00a048; UVB 311\u00a0nm, n\u00a0=\u00a07) oder Kombinationstherapien (PUVA mit systemischen Retinoiden, n\u00a0=\u00a018). H\u00e4ufigste Second\u2010Line\u2010Therapie war Interferon (INF)\u2010\u03b1 plus PUVA (n\u00a0=\u00a015). Der Behandlungsverlauf war insgesamt g\u00fcnstig (45,2\u00a0% Remission, 28,6\u00a0% stabile Erkrankung, 22,6\u00a0% Progress). Maligne Komorbidit\u00e4ten wurden im Vergleich zu einer gesunden Vergleichsgruppe h\u00e4ufiger beobachtet.<\/jats:p><\/jats:sec><jats:sec><jats:title>Schlussfolgerungen<\/jats:title><jats:p>Bis zur Diagnosestellung der PCL dauert es oft mehrere Jahre. Der Wert der Staging\u2010Verfahren ist gering. Die Behandlungsmodalit\u00e4ten in fr\u00fcheren MF\u2010Stadien basieren haupts\u00e4chlich auf der Phototherapie.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.14400_g","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T06:40:04Z","timestamp":1615531204000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stellenwert diagnostischer Verfahren und Risiko von Zweittumoren bei prim\u00e4r kutanen Lymphomen"],"prefix":"10.1111","volume":"19","author":[{"given":"Alexander","family":"Scheu","sequence":"first","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik T\u00fcbingen Eberhard Karls Universit\u00e4t T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-0195","authenticated-orcid":false,"given":"Saskia Maria","family":"Schnabl","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik T\u00fcbingen Eberhard Karls Universit\u00e4t T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Patric","family":"Steiner","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik T\u00fcbingen Eberhard Karls Universit\u00e4t T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko","family":"Fend","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie und Neuropathologie Eberhard Karls Universit\u00e4t T\u00fcbingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Berneburg","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik T\u00fcbingen Eberhard Karls Universit\u00e4t T\u00fcbingen"},{"name":"Klinik und Poliklinik f\u00fcr Dermatologie Universit\u00e4t Regensburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Sadegh","family":"Yazdi","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts\u2010Hautklinik T\u00fcbingen Eberhard Karls Universit\u00e4t T\u00fcbingen"},{"name":"Klinik f\u00fcr Dermatologie und Allergologie Uniklinik RWTH Aachen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"issue":"12","key":"e_1_2_8_4_1","first-page":"1266","article-title":"S2k Guidelines \u2013 Cutaneous Lymphomas Update 2016 \u2013 Part 1: Classification and Diagnosis (ICD10 C82 \u2010 C86)","volume":"15","author":"Dippel E","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"e_1_2_8_5_1","first-page":"112","article-title":"S2k Guidelines \u2013 Cutaneous Lymphomas Update 2016 \u2013 Part 2: Treatment and Follow\u2010up (ICD10 C82 \u2010 C86)","volume":"16","author":"Dippel E","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"e_1_2_8_6_1","first-page":"275","article-title":"Primary cutaneous diffuse large B\u2010cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences","volume":"17","author":"Felcht M","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"12","key":"e_1_2_8_7_1","first-page":"1207","article-title":"Cutaneous B\u2010cell lymphomas \u2013 pathogenesis, diagnostic workup, and therapy","volume":"14","author":"Nicolay JP","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"issue":"1","key":"e_1_2_8_9_1","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze R","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.076"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17240"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3653"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13044"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17258"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124696"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200001000-00005"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2010"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-007-0127-y"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.039"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27627"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2003.00614_10.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10706"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5905"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.027"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25577"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00561-w"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.3241"},{"issue":"3","key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ddg.13188","article-title":"Intralesional anti\u2010CD20 antibody for low\u2010grade primary cutaneous B\u2010cell lymphoma: Adverse reactions correlate with favorable clinical outcome","volume":"15","author":"Eberle FC","year":"2017","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-634394"},{"issue":"7","key":"e_1_2_8_37_1","first-page":"10705","article-title":"Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta\u2010analysis","volume":"8","author":"Fang C","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0155-3"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70017-6"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.011"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.3.335"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.075"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.04.004"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318217393f"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14400_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.14400_g","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.14400_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T06:28:58Z","timestamp":1693549738000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.14400_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/ddg.14400_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.14400_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2020-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}